Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. reports developments across its orthopedic and spine medical technology portfolio. The company provides spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System, for complex musculoskeletal conditions.
Recurring OFIX news includes quarterly results, guidance, product launches and commercial execution in Spine and Orthopedics. Company updates also cover pediatric limb reconstruction offerings such as FITBONE, planning software such as OrthoNext, the TRUELOK Elevate system, spine leadership realignment, distributor transitions, biologics activity and the discontinued M6 artificial disc product lines.
Orthofix (NASDAQ:OFIX) reported second quarter 2026 net sales of $210.9 million, up 3.8% reported and 4.7% on a pro forma constant currency basis versus 2025, driven by double‑digit constant currency growth in Global Spine Fixation and Global Limb Reconstruction and 3% growth in Therapeutic Solutions.
GAAP gross margin was 71.0% and non‑GAAP adjusted EBITDA was $20.1 million (9.6% of pro forma net sales), while reported net loss was $15.8 million, or $(0.39) per share. Cash, cash equivalents, and restricted cash totaled $104.4 million on June 30, 2026. Following Medicare reimbursement restoration for non‑invasive bone growth stimulators and Q2 performance, Orthofix raised its full‑year 2026 pro forma guidance, now expecting net sales of $845–$855 million and adjusted EBITDA of $95–$98 million, implying margin expansion versus 2025.
eXeX, a Surgery Intelligence company, appointed Max Reinhardt as President, Healthcare, to lead commercial execution of its Canopus platform across hospital systems in the United States, the United Kingdom and other markets. Reinhardt brings more than three decades of MedTech and pharmaceutical leadership, including 17 years at Johnson & Johnson and President-level roles at Orthofix Medical (NASDAQ: OFIX), Pacira BioSciences and DePuy Synthes.
Canopus by eXeX is described as the first Surgery Intelligence platform, delivering OR-, surgeon- and procedure-specific setup and step-by-step execution plans in real time using touch-free technology, without EHR integration or patient data. According to eXeX, the system aims to reduce surgeon cognitive load, support OR teamwork and improve OR productivity, and is already deployed across multiple hospital groups in the US and UK, having supported several thousand live surgeries, initially in complex spine and orthopedics.
eXeX also introduced Canopus Command, an intelligent portal giving hospital staff and leadership a live operational view into every surgical case, exposing real-time metrics such as setup accuracy, workflow timing, supply utilization and onboarding velocity. A key metric in Canopus Command is the “Surgical Inquiry” – the moment a team member pulls the exact information needed for the case – which can be tracked across facilities to show where information demand is concentrating by procedure, team and workflow stage, enabling leadership to allocate resources ahead of need. Reinhardt joins recently appointed COO John Spranger and Chairman/CEO Dr. Robert Masson to drive the company’s stated goal of bringing Canopus to every OR, for every surgeon and every surgery.
Orthofix (NASDAQ:OFIX) will participate in two investor conferences: the Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026 for 1x1 meetings, and Canaccord Genuity’s 46th Annual Growth Conference in Boston on August 12, 2026, featuring a 9:30 a.m. ET fireside chat.
The Canaccord Genuity session will be available via live and archived webcast in the “Events & Presentations” section of the Orthofix Investor Relations website. Orthofix also highlights that it regularly posts important investor information in the “Investors” section of its main website.
Orthofix (NASDAQ:OFIX) will release its Q2 2026 financial results on Wednesday, August 5, 2026, before the market opens. The company will host a conference call and webcast to review the results at 8:30 a.m. Eastern Time, with access details provided for U.S. and international participants.
A live webcast and the earnings release will be available at ir.orthofix.com. According to Orthofix, investors are encouraged to regularly visit the Investors section of www.orthofix.com for important updates and information.
Orthofix Medical (NASDAQ:OFIX) will participate in two June 2026 investor events: the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach on June 8, featuring an 8:40 a.m. ET fireside chat, and the Truist Securities MedTech Conference in Boston on June 16 for 1x1 meetings.
According to Orthofix, a live and archived webcast of the Goldman Sachs fireside chat will be available in the “Events & Presentations” section of its investor relations site. The company also highlights its “Investors” website section as a key channel for ongoing updates.
Orthofix (NASDAQ:OFIX) announced pediatric limb reconstruction product updates showcased at POSNA 2026 (May 6-8, 2026) in Orlando. Highlights include the newly launched FITBONE Trochanteric Intramedullary Lengthening System for femoral-lengthening with a trochanteric entry and OrthoNext 2.1 planning software enhancements.
The FITBONE Trochanteric system targets patients aged 12-21 and offers a smaller proximal diameter for greater procedural flexibility; OrthoNext 2.1 adds scheduling, automatic marker ID, 3D ring modeling and expanded deformity analysis for TL-HEX planning.
Orthofix (NASDAQ:OFIX) reported Q1 2026 net sales of $196.7M and non-GAAP pro forma net sales of $196.4M, a ~2.7% pro forma constant-currency increase versus Q1 2025. Reported net loss was $(20.9)M and non-GAAP pro forma adjusted EBITDA was $9.7M. Cash totaled $120.9M. The company reaffirmed full-year 2026 guidance: net sales $850–$860M, non-GAAP adjusted EBITDA $95–$98M, and positive free cash flow expected.
Orthofix (NASDAQ:OFIX) will release first quarter 2026 financial results on Tuesday, May 5, 2026 before market open. The company will host a conference call and webcast at 8:30 am Eastern Time the same day to review results.
Dial-in numbers: (888) 596-4144 (U.S.) or (646) 968-2525 (international); conference ID 7578740. A live webcast and the press release will be available at ir.Orthofix.com. Orthofix encourages investors to consult its Investors website for updates.
Orthofix (NASDAQ:OFIX) realigned Spine leadership, eliminating the President, Global Spine Solutions role and placing key Spine leaders to report directly to CEO Massimo Calafiore to speed decision-making and commercialization of the 7D navigation platform.
Preliminary Q1 2026 net sales were $196.7M (reported) and pro forma net sales were $196.4M, up 0.4% reported and 3% non-GAAP pro forma constant currency versus Q1 2025. 2026 guidance reaffirmed: $850M–$860M net sales, non-GAAP adjusted EBITDA $95M–$98M, ~+70 bps margin expansion at midpoint, and positive free cash flow excluding potential legal settlements.
Orthofix (NASDAQ:OFIX) reported fourth-quarter 2025 net sales of $219.9M and pro forma net sales of $218.6M, up 2.0% reported and 3.1% pro forma constant currency versus Q4 2024. Full-year 2025 reported net sales were $822.3M with pro forma net sales of $811.9M.
Full-year 2025 non-GAAP pro forma adjusted EBITDA was $85.9M (10.6% margin), full-year net loss was $(92.2M), and cash totaled $85.1M at year-end. 2026 guidance: net sales $850M–$860M, non-GAAP adjusted EBITDA $95M–$98M, and positive free cash flow (excl. potential legal settlements).